Evidence map›Paper›PMID 42237252›Full record

SynthesisBMC nephrology2026

Serum and urine prognostic biomarkers for autosomal dominant polycystic kidney disease: a systematic review and meta-analysis.

Jana Khawandi, Vinamratha Rao, Daniel G Rayner, Niveditha Girimaji, Muayad Azzam, Qais Hamarsha, Hassan Kawtharany, Ali Choaib, Mustafa Qadir, Alysha Khan and 9 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Jana Khawandi *Evidence-based Practice and Implementation Center, Department of Internal Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd MS3002, Kansas City, KS, 66160, USA.
Vinamratha Rao *Evidence-based Practice and Implementation Center, Department of Internal Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd MS3002, Kansas City, KS, 66160, USA.
Daniel G RaynerSchulich School of Medicine & Dentistry, Western University, London, ON, Canada.
Niveditha GirimajiEvidence-based Practice and Implementation Center, Department of Internal Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd MS3002, Kansas City, KS, 66160, USA.
Muayad AzzamEvidence-based Practice and Implementation Center, Department of Internal Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd MS3002, Kansas City, KS, 66160, USA.
Qais HamarshaEvidence-based Practice and Implementation Center, Department of Internal Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd MS3002, Kansas City, KS, 66160, USA.
Hassan KawtharanyEvidence-based Practice and Implementation Center, Department of Internal Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd MS3002, Kansas City, KS, 66160, USA.
Ali ChoaibEvidence-based Practice and Implementation Center, Department of Internal Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd MS3002, Kansas City, KS, 66160, USA.
Mustafa QadirEvidence-based Practice and Implementation Center, Department of Internal Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd MS3002, Kansas City, KS, 66160, USA.
Alysha KhanEvidence-based Practice and Implementation Center, Department of Internal Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd MS3002, Kansas City, KS, 66160, USA.
Madhulika SharmaDivision of Nephrology and Hypertension, The Jared Grantham Kidney Institute, Kansas University Medical Center, Kansas City, KS, USA.
Pamela TranDivision of Nephrology and Hypertension, The Jared Grantham Kidney Institute, Kansas University Medical Center, Kansas City, KS, USA.
Sorin FedelesCritical Path Institute, Polycystic Kidney Disease Outcomes Consortium, Tucson, AZ, USA.
Wendy RuyleCritical Path Institute, Polycystic Kidney Disease Outcomes Consortium, Tucson, AZ, USA.
Alan S L YuDivision of Nephrology and Hypertension, The Jared Grantham Kidney Institute, Kansas University Medical Center, Kansas City, KS, USA.
Kenneth R HallowsDivision of Nephrology, Department of Medicine, University of Vermont Larner College of Medicine, Burlington, VT, USA.
Ronald D PerroneDivision of Nephrology, Department of Medicine, Tufts Medical Center, Tufts University School of Medicine, Boston, MA, USA.
Farid ForoutanHealth Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
Reem A MustafaEvidence-based Practice and Implementation Center, Department of Internal Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd MS3002, Kansas City, KS, 66160, USA. rmustafa@kumc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAutosomal dominant polycystic kidney disease (ADPKD), the leading monogenic cause of kidney failure, exhibits heterogeneous clinical progression. This systematic review and meta-analysis synthesize and evaluate current evidence on blood and urine prognostic biomarkers in ADPKD, addressing gaps in understanding their role in predicting progression and guiding clinical trial selection and management.

methodsWe searched PubMed, Embase, and Cochrane up to April 2025 and screened articles in duplicate. We included longitudinal studies evaluating the blood and urine prognostic biomarkers in patients with ADPKD with at least 10 participants and 1 year of follow-up. We used the Quality in Prognosis Studies tool to assess risk of bias, random effects meta-analyses to pool effect estimates, and the GRADE approach to assess the certainty of evidence.

resultsWe included 58 studies, with 33 urinary biomarkers and 29 serum/blood biomarkers identified. The most frequently studied biomarkers were urine osmolality, copeptin, proteinuria, Monocyte Chemoattractant Protein-1, and uric acid, whereas the most studied outcomes were estimated Glomerular Filtration Rate and Total Kidney Volume. The urinary biomarkers that showed the largest association with ADPKD were Monocyte Chemoattractant Protein-1, Kidney Injury Molecule-1, albumin, and Beta 2 microglobulin. Serum biomarkers associated with outcomes were primarily copeptin and Fibroblast Growth Factor-23, with β-Hydroxybutyrate and bicarbonate exhibiting lesser association.

conclusionIn conclusion, this systematic review highlights the potential prognostic value of blood and urine biomarkers in ADPKD. It also verified the need for further validation of biomarker use in ADPKD. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Polycystic Kidney, Autosomal DominantBiomarkersDisease ProgressionGlomerular Filtration RateHumansPrognosisBiomarkersADPKDBiomarkerPrognosisSerumUrine

Identifiers

PMID42237252
PMCPMC13450485

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.